Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Big Technologies considers action against suspended CEO; Shares tank

(Sharecast News) - Shares in Big Technologies plunged on Friday as the company said it was considering action against suspended chief executive officer and founder Sara Murray. The company said it could no longer rely on a statement signed by Murray on behalf of the company in a litigation, that relates to her interests in and relationship with Zinc Ltd, Monitoring Partners Ltd, RCP Ltd and Romelle Ltd.

These four entities held shares in Big Technologies at the company's initial public offering on London's AIM Market in July 2021 of around 17.7% of the issued share capital at that time.

"In light of the information from its further investigations, the company is considering its position in relation to the litigation as well as other steps which it may be appropriate to take, including the possibility of claims or actions against and in relation to Sara Murray and others," Big Technologies said.

"As part of its continuing investigations, the company has asked Sara Murray to clarify the exact nature of her interests in and relationship with the four entities referred to."

The company on Tuesday said Murray was suspended from her role, owing to concerns in respect of her conduct with litigation relating to the company's acquisition of Buddi. Big is currently defending a High Court claim brought by a small number of former Buddi shareholders.

Murray held currently holds around 26.8% of BIG.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.